Reported about 5 hours ago
Illumina has revised its financial outlook downwards, anticipating annual profits of approximately $4.50 per share, following China's import ban on its genetic sequencing instruments. To offset potential revenue losses from the Greater China market, the company plans to cut $100 million in costs. Despite this, Illumina's shares saw a 3.5% increase after the announcement.
Source: YAHOO